TCT2023 | The values of μFR® in CTO, TAVR/TAVI Populations

2023-10-27 10:00

Topic 1: Prognosis value of μFR® in the patients after CTO-PCI

Dr. Jiasheng Yin From Zhongshan Hospital Fudan University gives a presentation about the prognosis value of μFR® (AngioPlus system from Pulse Medical) after stent implantation on CTO-PCI. 231 patients with 237 CTO-PCI lesions were enrolled. Target vessel failure (TVF) was the primary endpoint. The study result shows that most patients’ post-PCI μFR® was more than 0.90, with the median of 0.97. Post-PCI μFR® was an independent predictors of TVF with best cut-off value of ≤0.92. So Post-PCI μFR® can predict the incidence of adverse events after successful stent implantation in CTO lesions. A prospective, cohort study comparing μFR® vs. FFR as a better predictor of prognosis in CTO-PCI has been launched.



Topic 2: Comparison of μFR and FFR after successful PCI in CTO patient

Dr. Jiasheng Yin also gives another presentation “Comparison of FFR and μFR® after successful PCI in patients with CTO”. With 83 CTO lesions from 80 patients enrolled. The study tries to exploring the correlation between μFR® and FFR after successful CTO recanalization and DES implantation. μFR® and FFR were measured. There’re significant differences between angiography-based μFR® and FFR after successful CTO-PCI. Multivariate regression showed that collateral circulation grade was an independent risk factor contributing to these differences.




Topic 3: μFR in patients with severe aortic stenosis undergoing TAVR

Dr. Fukuishi Yuta from Kobe University Graduate School of Medicine in Japan, on behalf of the team, presented the results of a validation of the diagnostic accuracy of μFR® in patients with severe aortic stenosis undergoing TAVR (Transcatheter Aortic Valve Replacement). As a single-center retrospective study, 38 vessels treated with TAVR in 25 patients were included. Pre-TAVR μFR® was used as the primary endpoint, and post-TAVR invasive FFR ≤0.8 was used as a reference standard of ischemia. The accuracy of Pre-TAVR μFR® was 84.2%, and the analysis speed was significantly fast. The results of the study indicated single-view μFR® is a feasible option for evaluating comorbid CADs in patients with severe AS undergoing TAVR.



Topic 4: μFR-derived functions to assess the changes on FFR and iFR in patients undergoing TAVI

Dr. Simone Fezzi from the University of Verona, Italy, presented the results of a study on behalf of a team that used μFR-derived functions to assess the changes on FFR and iFR in patients undergoing TAVI. As a retrospective, single-center study, 136 vessels from 67 patients were included for pre-and post FFR and iFR. During the evaluation, the study used multiple measures of μFR® to determine the physiological patterns of CAD. The results showed that diffuse CAD without major gradients is the prevalent pattern of disease in patients with SAS undergoing TAVI. FFR decrease after TAVI correlated with a higher local disease severity (major drops), while iFR changes gave more unpredictable results.



Verification code: